The traditional pharmaceutical industry model—production of blockbuster drugs that serve many patients and generate large revenues—will give ground to the personalized medicine model, in which drugs are targeted to the patients who will benefit most. Next-generation sequencing (NGS) will be a critical, early-stage tool for companies that adopt the new model, one that will help to improve the discovery and development process and enable the development of new, high-value products.
While wet lab prices are steadily decreasing, bioinformatic and statistical analyses have become a serious bottleneck. There are two axes: technology and applications. The first axis will embrace bioinformatic, statistical and computational problems. The second one will raise some of the most emblematic areas where NGS has exerted a dramatic influence.